Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

Berenberg lowered the firm’s price target on Moderna (MRNA) to $28 from $30 and keeps a Hold rating on the shares. The firm thinks BioNTech’s ...

Moderna integrates extensive research and development with both in-house and partner manufacturing to rapidly develop and ...

Fintel reports that on November 10, 2025, B of A Securities maintained coverage of Moderna (NasdaqGS:MRNA) with a ...

As you might know, Moderna, Inc. (NASDAQ:MRNA) just kicked off its latest quarterly results with some very strong numbers.

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

The 9 therapeutics stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 5.7%. In ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Thursday reported a loss of $200 million in its third quarter. On a per-share basis, the Cambridge, Massachusetts-based company ...

Therapeutics company Gilead Sciences (NASDAQ:GILD) jumped 3.4%. Is now the time to buy Gilead Sciences? Access our full ...

As of Friday, November 07, CytomX Therapeutics, Inc.’s CTMX share price has dipped by 18.38%, which has investors questioning ...

European technology stocks led sectoral declines, falling 1.9 per cent. The healthcare sector rose 0.4 per cent. Novo Nordisk ...